Sign In

10.8 : Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The pathophysiology of HF involves four major interrelated systems: the heart, vasculature, kidney, and neurohumoral regulatory circuits. Myocardial overload, hypertension, valvular defects, or genetic cardiomyopathies cause insufficient cardiac output, leading to compensatory cardiac myocyte hypertrophy, metabolic reprogramming, and altered gene expression.

Increased fibroblast proliferation and extracellular matrix deposition result in fibrosis, disrupting cardiomyocyte communication and causing cell death via apoptosis or necrosis. Vascular stiffness stems from impaired crosstalk between luminal endothelial and underlying smooth muscle cells, involving receptors that increase intracellular Ca2+ levels. Endothelial dysfunction disrupts the balance between vasodilating NO and vasoconstricting reactive oxygen species (ROS), increasing afterload. The kidney regulates Na+ and H2O levels, maintaining adequate GFR and diuresis through autoregulatory and neurohumoral mechanisms. If untreated, chronic activation of the sympathetic nervous system and RAAS leads to fatal cardiac tissue remodeling. Neurohumoral regulation creates a vicious cycle of vasoconstriction, increased afterload, volume overload, tachycardia, and positive inotropic actions. Common heart failure symptoms include tachycardia, decreased exercise tolerance, shortness of breath, maldigestion ascites, and peripheral and pulmonary edema. Heart failure ranges from Class I to IV. At the same time, the AHA and ACC extended this classification by adding stages A (preventable risk factors), B (asymptomatic stage requiring treatment), C (oscillations between symptoms in class II and III), and D (final stage requiring heart transplantation and left ventricular assist device implantation).

Tags
Heart FailurePathophysiologyEjection FractionSystolic Heart FailureDiastolic Heart FailureMyocardial OverloadHypertensionValvular DefectsCardiac OutputCompensatory MechanismsCardiac Myocyte HypertrophyFibrosisEndothelial DysfunctionNeurohumoral RegulationRAASSympathetic Nervous SystemHeart Failure SymptomsAHA Classification

From Chapter 10:

article

Now Playing

10.8 : Pathophysiology of Heart Failure

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

499 Views

article

10.1 : Electrophysiology of Normal Cardiac Rhythm

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

298 Views

article

10.2 : Mechanism of Cardiac Arrhythmias

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

256 Views

article

10.3 : Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

266 Views

article

10.4 : Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

147 Views

article

10.5 : Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

226 Views

article

10.6 : Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

133 Views

article

10.7 : Pathophysiology of Cardiac Performance

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

216 Views

article

10.9 : Heart Failure Drugs: Inotropic Agents

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

170 Views

article

10.10 : Heart Failure Drugs: Diuretics

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

119 Views

article

10.11 : Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

122 Views

article

10.12 : Heart Failure Drugs: β-Blockers

Cardiovascular Drugs: Antiarrhythmic and Heart Failure Drugs

83 Views

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved